Publication
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
Journal Paper/Review - Aug 1, 2007
Roth Arnaud D, de Braud Filippo, Seymour Matthew, Widmer Lukas, Glynne-Jones Robert, Leslie Martin, Wernli Martin, Maibach Rudolf, Rufibach Kaspar, Borner Markus M, Köberle Dieter, Saletti Piercarlo, Bernhard Jürg, Falk Stephen, Stupp Roger, Fazio Nicola, Swiss Group for Clinical Cancer Research
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Electronic
Pages
Brief description/objective
PURPOSE: This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according to overall response rate (ORR) for comparison in a phase III trial with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy. PATIENTS AND METHODS: Chemotherapy-naïve patients with measurable unresectable and/or metastatic gastric carcinoma, a performance status